advertisement
Abstract #8947 Published in IGR 5-2
Brimonidine Purite and bimatoprost compared with timolol and latanoprost in patients with glaucoma and ocular hypertension
Netland PA; Mroz M; Rosner SA; Katzman B; Macy JIAdvances in Therapy 2003; 20: 20-30
This three-month multicenter, investigator masked, parallel group study compared brimonidine Purite and bimatoprost (brimP/bim) with timolol gel forming solution and latanoprost (tim/latan) in 28 patients with open-angle glaucoma or ocular hypertension. Intraocular pressure (IOP) was measured at baseline and two hours after morning instillation at weeks 2, 4, and 12. The primary outcome measure was the mean IOP reduction from baseline. Secondary measures were the percentage of patients in each group who achieved specific low target pressures and the incidence of adverse events. Mean IOP at baseline was 24.8 mmHg in each group. At follow-up visits, mean reductions from baseline ranged from 8.5-9.0 mmHg with brimP/bim and from 7.5-7.7 mmHg with tim/latan. More patients achieved low target pressures with brimP/bim. At week 12, 69.2% of brimP/bim patients and 27.3% of tim/latan patients had IOPs of 16 mmHg or lower (p = 0.024). Both regimens were well tolerated, and adverse events were infrequent. The combination of brimonidine Purite and bimatoprost was well tolerated and at least as effective as Timoptic XE and latanoprost in reducing IOP. More patients achieved low target IOPs with brimonidine Purite and bimatoprost than with Timoptic XE and latanoprost. A larger study is needed to confirm these results.
Dr. P.A. Netland, Department of Ophthalmology, University of Tennessee Health Science Center, 956 Court Avenue, Memphis, TN 38163, USA
Classification:
11.3.3 Apraclonidine, brimonidine (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.3.4 Betablocker (Part of: 11 Medical treatment > 11.3 Adrenergic drugs)
11.4 Prostaglandins (Part of: 11 Medical treatment)